Episode Details

Nationwide Bloodwork, no doctor visit → https://ddtmtd.co/Amplify

Need reliable, third-party tested research compounds: Janus Optimize Code DDTSkool

Join my Enhancement Education Community → https://ddtmtd.co/skool

Implement the protocols → https://ddtmtd.co/apply

Big Pharma just came for retatrutide. Eli Lilly filed six lawsuits against research peptide sellers, a med spa chain, and a compounding pharmacy, compounders got cut off from tirzepatide and semaglutide, and a biologics classification is coming that would make Lilly the only place to get reta. Jay Campbell is back on the DDT Method Podcast to break down who Lilly is targeting and why, what a biologic classification does to generics and compounders, why renaming your GLP-3 isn't a workaround, how Lilly let the research market do its marketing for free for three years, and why the play now is four- and five-pathway agonists and oral delivery, starting with BioLean 4XR, the oral strip BioLongevity Labs is building to replace what Lilly took off the table.

5 Key Takeaways

• The one question Jay asked a stranger who had lost 60 pounds on retatrutide

• What a year of DEXAs and full-body scans on FLGR-242 users showed about the organ-growth
• Why Eli Lilly waited three years to act on retatrutide, and what a biologic classification means for RUO
• Jay’s six-day experiment on SLU-PP-915 vs high-dose SLU-PP-332
• The line between sharing your protocol and making a claim for influencers

Chapters

0:00 Foundation before enhancement: Jay's new book and the 54-year-old on reta
9:47 FLGR-242 one year in: what it is, what it fixed, and what users are seeing
18:35 Non-responders, why DEXA misleads, and how to dose FLGR-242
24:29 How albumin binding made FLGR-242 possible, and Drew's upcoming log
33:08 Bio-IGF: the once-a-week IGF product coming next
38:00 Clotho for the already-optimized: senses, sexual performance, and the kidney trial
44:54 Grounding, sunlight, melanotan, and Drew's foundation reset
50:31 Big Pharma just killed retatrutide: Eli Lilly, biologic classification, and BioLean 4XR
58:59 The six lawsuits, 14,000 websites, and compounders cut off
1:06:22 The influencer legal line: what you can and can't say
1:11:46 SLU-PP-915 vs high-dose SLU-PP-332: the verdict
1:18:23 ATX at high dose, high-dose SS31, and the BioRecharge stack
1:24:28 MOTS-c protocols and phasing AMPK against mTOR
1:29:16 The future of delivery: patches, sprays, and the black market risk
1:36:00 Living Leaner, Longer, Stronger and where to find Jay

Connect with Jay Campbell

Website: https://jaycampbell.com

Living Leaner, Longer, Stronger on Amazon: https://www.amazon.com/dp/B0HDJ41BWS

Fully Optimized Health (private membership): https://jaycampbell.com/foh/

Instagram: https://www.instagram.com/jaycampbell1971/ (

X: https://x.com/JayCampbell333

Substack: https://substack.com/@jaycampbell333